Synergistic composition for inhibiting ovarian cancer and tumor stem cells of ovarian cancer, method and application
Through the combination of pamiparib and anlotinib, ovarian cancer stem cells are inhibited and PI3K/AKT signaling pathway is affected, the problems of ovarian cancer recurrence and drug resistance are solved, effective treatment of ovarian cancer is achieved, and the current situation is compensated. There are technical defects.
Patent Information
- Application Number
- CN202410933526.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively inhibit the recurrence and drug resistance of ovarian cancer and its tumor stem cells, especially in advanced ovarian cancer, which lacks effective therapeutic strategies for tumor stem cells.
The combination of pamiparib and anlotinib is used to inhibit the characteristics of ovarian cancer stem cells and affect the PI3K/AKT signaling pathway, synergistically inhibit the proliferation, cloning and migration of ovarian cancer, and achieve the treatment of ovarian cancer recurrence and Purpose of drug resistance.
It has achieved synergistic inhibition of ovarian cancer and its tumor stem cells, significantly reduced the recurrence and drug resistance of ovarian cancer, provided a new combination drug strategy, made up for the gap in the existing technology, and verified in vivo Its safety and effectiveness.
Smart Images

Figure CN118986995A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular to a composition, method and application for enhancing the inhibition of ovarian cancer and tumor stem cells thereof, in particular to the application of pamiparib or niraparib combined with anlotinib in treating recurrence and drug resistance of ovarian cancer. Background Art
[0002] Ovarian cancer is the fifth most common cancer in women and the eighth most common cause of cancer death, with a five-year survival rate of less than 45%. Due to the lack of typical symptoms and effective diagnostic methods in the early stages, about 70% of patients are already in the advanced stage when diagnosed. Conventional first-line treatment is tumor cell reduction surgery and postoperative adjuvant platinum-based chemotherapy, but 70% of patients still relapse within 3 years. For patients who become resistant to chemotherapy after recurrence, the 5-year survival rate is only 29%. Therefore, there is a significant clinical need to find new and more effective treatment strategies.
[0003] Pamiparib (BGB-290) is a highly selective polyADP-ribose polymerase (PARP) inhibitor developed by BeiGene (Beijing) Co., Ltd., and its clinical trial in Chinese patients with advanced high-grade ovarian cancer and triple-negative breast cancer is ongoing. Mutations in the breast cancer susceptibility genes (BRCA) are important risk factors for ovarian cancer. BRCA1 and BRCA2 are tumor suppressor genes that encode proteins involved in the repair of double-stranded DNA breaks by homologous recombination. BRCA mutations disrupt the DNA repair pathway of homologous recombination repair, and when the repair pathway of single-strand breaks is blocked by PARP inhibition, tumor cells use the homologous recombination repair pathway. PARP inhibitors take advantage of this susceptibility of homologous recombination-deficient tumor cells and cause cell death through synthetic lethal interactions. The most widespread mechanism of action of PARP inhibitors is inhibition of DNA damage repair, which is also a treatment strategy for advanced ovarian cancer with homologous recombination deficiency.
[0004] Angiogenesis is a key hallmark of cancer, and anti-angiogenic therapy is used as a standard treatment for a variety of cancers. Anlotinib is a new small molecule multi-target tyrosine kinase inhibitor (TKI) independently developed in my country, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor and c-kit, and inhibiting tumor growth by inhibiting signaling pathways related to angiogenesis and cell proliferation. A large amount of preclinical research data has reported the connection between PARP inhibitors and angiogenesis, and the synergistic effect between PARP inhibition and anti-angiogenesis has been demonstrated in several cancer models. Several clinical trials are exploring the effects of anti-angiogenic therapy combined with PARP inhibitors in cancer treatment. For example, a phase I / II study showed the beneficial effects of the combination of cediranib and olaparib in women with recurrent ovarian cancer and breast cancer, and improved the progression-free survival of women with recurrent platinum-sensitive ovarian cancer. Clinical trials have found that anlotinib also has a certain effect in ovarian cancer and has good anti-tumor activity.
[0005] Cancer Stem Cell (CSC), also known as tumor stem cell, refers to cancer cells with stem cell properties, which have the ability of "self-replication" and "multi-cell differentiation". Such cells are generally considered to have the potential to form tumors and develop into cancer. CSC is closely related to pathological features that lead to poor clinical prognosis, and is also an important reason for the resistance of traditional anticancer therapies. CSC has an intrinsic resistance mechanism to radiotherapy and chemotherapy, which gives CSC a survival advantage over its differentiated counterparts. In addition, CSC can lead to the diversification of the composition of cells in tumor tissues, resulting in subclones with different phenotypes, thereby increasing the possibility of resistance and recurrence after anticancer treatment.
[0006] Ovarian cancer is one of the common gynecological malignancies because it is highly invasive, recurrent and drug-resistant. Its recurrence and drug-resistance characteristics are closely related to the presence of CSCs. Therefore, the discovery of a composition that inhibits ovarian cancer and its tumor stem cells has important clinical application value for improving the treatment effect of ovarian cancer, and is of great significance for reducing the recurrence and metastasis of ovarian cancer patients and improving the prognosis.
[0007] Through searching, the following public documents related to the patent application of the present invention are found:
[0008] Graduation thesis: Zhu Yanghui, Study on the effect and mechanism of anlotinib hydrochloride against ovarian cancer, Master's thesis of Sichuan University, 2021. This paper reports the effect and mechanism of anlotinib against ovarian cancer, but does not study its combination with other drugs. Summary of the invention
[0009] The purpose of the present invention is to overcome the deficiencies in the prior art and to provide a composition, method and application for enhancing the inhibition of ovarian cancer and its tumor stem cells.
[0010] The technical solution adopted by the present invention to solve its technical problem is:
[0011] A synergistic composition for inhibiting ovarian cancer and tumor stem cells thereof, the composition is composed of pamiparib and anlotinib in combination.
[0012] Furthermore, the mass ratio of pamiparib and anlotinib when used in combination is 0.1-50:1.
[0013] Furthermore, when the composition is used, the administration method of the combination of pamiparib and anlotinib is simultaneous administration or sequential administration.
[0014] Use of the above-mentioned composition in the preparation of a drug for treating recurrence and / or drug resistance of ovarian cancer.
[0015] Furthermore, pamiparib and anlotinib in the composition inhibit the characteristics of human ovarian cancer stem cells, thereby synergistically inhibiting the proliferation, cloning and migration of ovarian cancer, and achieving the treatment of ovarian cancer recurrence and drug resistance by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
[0016] Use of the above-mentioned composition in the preparation of a drug for inhibiting the growth of ovarian cancer tumors in BALB / C nude mice in vivo.
[0017] Furthermore, pamiparib and anlotinib in the composition synergistically inhibit the growth of ovarian cancer in nude mice by inhibiting the characteristics of ovarian cancer stem cells, and achieve the purpose of synergistically treating ovarian cancer by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
[0018] Use of the above-mentioned composition in the preparation of a drug for inhibiting ovarian cancer tumor stem cells.
[0019] Use of the above-mentioned composition in preparing a drug for inhibiting the migration of ovarian cancer cells.
[0020] Use of the above-mentioned composition in preparing a drug for inhibiting ovarian cancer cell clone formation.
[0021] The advantages and positive effects achieved by the present invention are:
[0022] 1. The present invention provides a combined drug strategy with synergistic effect for inhibiting ovarian cancer and its tumor stem cells, that is, the combined use of pamiparib and anlotinib can synergistically enhance the effect, not only inhibit the proliferation, cloning and metastasis of ovarian cancer, but also inhibit ovarian cancer stem cells, thereby inhibiting the recurrence and drug resistance of ovarian cancer, solving the difficult problem of high recurrence and drug resistance of ovarian cancer.
[0023] 2. Ovarian cancer is highly invasive, recurrent and drug-resistant, all of which are closely related to tumor stem cells. Currently, there are no marketed drugs targeting tumor stem cells available clinically. The present invention provides a new combination drug strategy to fill the gap in existing technologies and applications.
[0024] 3. In the present invention, the combination of pamiparib and anlotinib can synergistically enhance the effect and achieve the effect of 1+1>2.
[0025] 4. In the present invention, the combined use of pamiparib and anlotinib does not increase toxicity, and the patient's tolerance to one of the drugs can also be improved by reducing the dosage of a single drug of pamiparib or anlotinib.
[0026] 5. The medication strategy of pamiparib combined with anlotinib provided by the present invention can expand the new indications of marketed drugs and increase the market application prospects of similar drugs.
[0027] 6. The present invention uses two different types of drugs in combination, namely, the PARP inhibitor pamiparib and the small molecule tyrosine kinase inhibitor anlotinib to inhibit human ovarian cancer stem cells. Breast Cancer Susceptibility Gene (BRCA) wild-type ovarian cancer cells SK-OV3, OV-CAR5, and A2780 cells were selected. In vitro, the optimal dose of the combination of the two drugs was first detected by cell activity experiments. Further experimental results showed that pamiparib combined with anlotinib can effectively inhibit the cloning of ovarian cancer cells and inhibit lateral and vertical migration. Tumor spheroid formation experiments, limiting dilution experiments, and real-time quantitative fluorescence PCR experiments all verified that the combination of the two drugs has synergistic inhibitory activity on ovarian cancer stem cells. In vivo experiments on xenograft tumors in tumor-bearing mice also verified that the combination of the two drugs can achieve a synergistic effect. In addition, protein immunoblotting was used to further verify that the combination of the two drugs can synergistically inhibit tumor stem cell-related pathways. Therefore, the present invention provides a new drug strategy for treating human ovarian cancer by inhibiting the characteristics of tumor stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a graph showing the inhibitory effects of pamiparib and anlotinib alone in different ovarian cancer cells in the present invention;
[0029] Figure 2The figure shows the effect of pamiparib (PAM) and anlotinib (ANL) alone and in combination (PAM+ANL) on the colony formation of A2780 cells in the present invention; wherein, (a) a staining photo of cell clone colonies; (b) the number of cell clone colonies; wherein, compared with the solvent control group, ***P<0.01; compared with the single drug group, ### P < 0.01;
[0030] Figure 3 The figure shows the effect of pamiparib (PAM) and anlotinib (ANL) alone and in combination (PAM+ANL) on A2780 cell migration in the present invention; wherein, (a and b) scratch test at 2 μM concentration; (c and d) scratch test at 0.5 μM concentration; (e and f) Transwell test at 0.5 μM concentration; wherein, compared with the solvent control group, ***P<0.01, **P<0.05, *P<0.01; compared with the single drug group, ### P<0.01, ## P<0.05, # P<0.01; Control is the solvent control group;
[0031] Figure 4 The figure shows the effect of pamiparib (PAM) and anlotinib (ANL) alone and in combination (PAM+ANL) on the stem cell characteristics of ovarian cancer A2780 cells in the present invention; wherein, (a and b) the effect on spheroid size and spheroid efficiency; (c) the result of the limiting dilution experiment, the blue solid line and the blue dotted line represent the solvent control group, the green solid line and the green dotted line represent PAM, the black solid line and the black dotted line represent ANL, and the red solid line and the red dotted line represent the combination of the two drugs. The slope of the solid line represents the probability of tumor stem cell spheroid formation, and the slope of the dotted line represents the confidence interval for tumor stem cell spheroid formation; wherein, compared with the solvent control group (Control), ***P<0.01, *P<0.01; compared with the single drug group, ### P<0.01, ## P < 0.05;
[0032] Figure 5 The in vivo pharmacodynamic diagrams of Pamiparib (PAM) and Anlotinib (ANL) as single drugs and in combination (PAM+ANL) of the present invention; wherein, (a) a tumor appearance diagram of tumor inhibition in tumor-bearing mice; (b) an inhibition curve diagram of tumor volume in tumor-bearing mice; (c) an effect diagram of tumor weight in tumor-bearing mice; wherein, compared with the model group or the single drug group, ***P<0.01, **P<0.05, *P<0.01;
[0033] Figure 6The figures are evaluation diagrams of the in vivo toxicity of the combination of pamiparib and anlotinib in the present invention; wherein, (a) is the effect on the body weight of tumor-bearing mice; (b) is the effect on the level of aspartate aminotransferase (AST) in the liver of tumor-bearing mice; (c) is the effect on the level of alanine aminotransferase (ALT) in the liver of tumor-bearing mice;
[0034] Figure 7 The present invention is a diagram for evaluating the in vitro mechanism of action of pamiparib and anlotinib as single drugs and in combination; wherein, (a and c) are diagrams of bands expressing different proteins; (b and d) are diagrams of grayscale analysis of bands expressing different proteins; wherein, PI3K: phosphatidylinositol kinase; p-PI3K: phosphorylatedphosphatidylinositol kinase; Akt: serine / threonine kinase, p-Akt: phosphorylated serine / threonine kinase; N-cadherin: neural calciummucin; E-cadherin: epithelial calcium adhesion protein; Bcl-2: B-lymphoblastoma-2gene; Bax: BCL2-associated X (B lymphocytoma-2-associated X gene); SOX2: Sexdetermining regionY-box 2 (sex determining regionY box 2); ALDH1A1: aldehyde dehydrogenase 1A1 (acetaldehyde dehydrogenase 1A1); HIF1-α: hypoxia-inducible factor 1subunit alpha (hypoxia inducible factor 1 subunit alpha); Tubulin: microtubule protein (microscopic protein). Compared with the solvent control group,
[0035] ***P<0.01, **P<0.05, *P<0.01; compared with the single drug group, ### P<0.01, ## P<0.05, # P<0.01. DETAILED DESCRIPTION
[0036] The present invention will be further described below in conjunction with the embodiments. The following embodiments are descriptive rather than restrictive, and the protection scope of the present invention cannot be limited by the following embodiments.
[0037] The various experimental operations involved in the specific embodiments are all routine techniques in the art. For parts not specially annotated in this document, ordinary technicians in the art can implement them by referring to various commonly used reference books, scientific and technological literature or related instructions, manuals, etc. before the filing date of this invention.
[0038] A synergistic composition for inhibiting ovarian cancer and tumor stem cells thereof, the composition is composed of pamiparib and anlotinib in combination.
[0039] Preferably, the mass ratio of pamiparib and anlotinib when used in combination is 0.1-50:1.
[0040] Preferably, when the composition is used, the combination of pamiparib and anlotinib is administered simultaneously or sequentially.
[0041] Use of the above-mentioned composition in the preparation of a drug for treating recurrence and / or drug resistance of ovarian cancer.
[0042] Preferably, pamiparib and anlotinib in the composition inhibit the characteristics of human ovarian cancer stem cells, thereby synergistically inhibiting the proliferation, cloning and migration of ovarian cancer, and achieving the treatment of recurrence and drug resistance of ovarian cancer by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
[0043] Use of the above-mentioned composition in the preparation of a drug for inhibiting the growth of ovarian cancer tumors in BALB / C nude mice in vivo.
[0044] Preferably, pamiparib and anlotinib in the composition synergistically inhibit the growth of ovarian cancer in nude mice by inhibiting the characteristics of ovarian cancer stem cells, and achieve the purpose of synergistically treating ovarian cancer by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
[0045] Use of the above-mentioned composition in the preparation of a drug for inhibiting ovarian cancer tumor stem cells.
[0046] Use of the above-mentioned composition in preparing a drug for inhibiting the migration of ovarian cancer cells.
[0047] Use of the above-mentioned composition in preparing a drug for inhibiting ovarian cancer cell clone formation.
[0048] Specifically, the relevant preparation and detection are as follows:
[0049] Example 1 Screening of drug concentrations for combined use of pamiparib and anlotinib
[0050] Three human ovarian cancer cell lines, SK-OV3, OV-CAR5, and A2780, were selected. Cells in the logarithmic growth phase were selected and the cell density was adjusted to 5×10 4 / mL were evenly inoculated in a 96-well plate, and the experimental group (adding different concentrations of drugs) and the solvent control group (adding an equal volume of dimethyl sulfoxide, a solvent for dissolving drugs, and no drugs were added) were set up at the same time. 100μL of cell solution was added to each well, and 100μL of culture medium was added to each well of the blank group (containing only an equal volume of culture medium without cell solution, in order to deduct the effect of drug color on the results). After 24 hours, after the cells adhered to the wall, 0.5μL of pamiparib and anlotinib with concentrations of 128μM, 12.8μM, 1.28μM, 0.128μm, and 0.0128μM were added to each well of the 96-well plate, and each group was repeated three times. After 48 hours, 5mg / mL MTT (thiazolyl blue) solution was added. After 4 hours, the OD value was detected at dual wavelengths of 492nm and 630nm using an enzyme reader. Calculation formula: Cell survival rate (%) = (OD of experimental group - OD of blank group) / (OD of solvent control group - OD of blank group) × 100%.
[0051] The solvent control group, experimental group and blank group in the in vitro experiments in other embodiments of the present invention are the same as those in this embodiment.
[0052] The results are as follows Figure 1 As shown in Figure 2, among the three ovarian cancer cells, pamiparib was the least active and the least sensitive in A2780 cells, with an IC 50 (half inhibitory concentration) value is 45.47μM. Anlotinib has similar activity in three ovarian cancer cells. Therefore, A2780 cells and pamiparib combined with anlotinib and were selected for follow-up studies. 0.5, 1, 2, 4, 8μM pamiparib and 0.25, 0.5, 1, 2, 4, 8μM anlotinib were selected for one-to-one combination and screening, and the optimal compatibility ratio of pamiparib and anlotinib was determined. As shown in Table 1, when the concentration of pamiparib was 2μM, the cell survival rate was 92.24% after 48h of cell action. When the concentration of anlotinib was 2μM, the cell survival rate was 75.86% after 48h of cell action. The two drugs acted on the cells together for 48h, and the cell survival rate was only 55.94%, and the CI value was 0.57, indicating that the combination of the two drugs at this concentration has a synergistic effect. In the following experiments, pamiparib was combined with anlotinib to act on A2780 cells, and the concentration of both drugs was 2 μM.
[0053] Table 1 Combination index values of pamiparib and anlotinib
[0054]
[0055] Example 2 Pamiparib combined with anlotinib inhibits ovarian cancer cell clone formation
[0056] Take logarithmically growing cells, adjust the cell density to 1000 cells / mL and evenly inoculate them in a low-adhesion 6-well plate, and add 2mL of cell solution to each well. Place in a cell culture incubator and culture for 24h. After the cells adhere to the wall, set up a solvent control group and an experimental group. Add 10μL of dimethyl sulfoxide, an equal volume of 2μM pamiparib or 2μM anlotinib alone, and a mixed solution of 2μM pamiparib and 2μM anlotinib to the 6-well plate. Re-aspirate the culture medium every 2-3 days, add fresh culture medium and solution, and culture for 7-10 days. When more colonies appear in the solvent control group), stop culturing. Use a pipette to aspirate the cell culture medium (DMEM), wash each well twice with phosphate buffered saline (PBS), add 4% paraformaldehyde solution to fix for 30min, and then wash each well twice with PBS. Add 1mL 0.1% crystal violet to stain for 10 minutes, wash with PBS, dry and take pictures. Cloning rate = (number of clones / number of inoculated cells) × 100%.
[0057] The results are as follows Figure 2 As shown in the figure, when pamiparib (2 μM) was used alone, the number of cell clones was 125. When anlotinib (2 μM) was used alone, the number of cell clones was 106. When pamiparib (2 μM) and anlotinib (2 μM) were used in combination, the number of cell clones was only 2. This experiment used a low-adhesion well plate. The results of the clone formation experiment showed that the combination group had a significant inhibitory effect on the migration and long-term proliferation of ovarian cancer compared with the single-drug group.
[0058] At the same time, it was also demonstrated that when pamiparib (2 μM) and anlotinib (2 μM) were used in combination, the two drugs had a synergistic effect.
[0059] Example 3 Pamiparib combined with anlotinib inhibits the migration of ovarian cancer cells
[0060] The present invention uses a scratch test to detect the lateral migration ability and a Transwell test to detect the longitudinal migration ability. Scratch test: logarithmically growing cells are taken and cultured with 1% serum culture medium at 3×10 5 The density of cells / mL was evenly spread in a 6-well plate and cultured in a 37°C, 5% CO2 cell culture incubator for 24 hours. After the cells adhered to the wall, a solvent control group and an experimental group were set up, and vertical scratches were made in the same way. 10 μL of 2 μM pamiparib and 2 μM anlotinib monotherapy and 2 μM pamiparib and 2 μM anlotinib mixed solution were added. The completion of drug addition was taken as 0h, and the migration distance was recorded using the Situ Image Acquisition System software. Photos were taken at 12h, 24h, and 48h after drug addition, and the migration distance was recorded. The method for calculating the migration distance is: the migration distance at different times - the migration distance at 0h.
[0061] Transwell experiment: First, add 600 μL of culture medium containing 20% serum to the lower chamber of the Transwell chamber, take cells in the logarithmic growth phase and use serum-free cell solution at a concentration of 1×10 5 The density of cells / mL was evenly spread in the upper chamber of the chamber, 200μL in each upper chamber. After the cells adhered to the wall, 1μL of dimethyl sulfoxide was added to the solvent control group. An equal volume of 2μM pamiparib and 2μM anlotinib single drugs and 2μM pamiparib and 2μM anlotinib mixed solutions were added to the experimental group. After 24h, the culture medium in the upper and lower chambers was first aspirated, and the inside and outside of the chamber were washed with 1×PBS for a total of 3 times. Fix with 4% paraformaldehyde at room temperature for 30min, discard the 4% paraformaldehyde, and wash twice with PBS. Add 0.1% crystal violet solution to the upper and lower chambers and stain for 10min. After staining, dry and take pictures.
[0062] like Figure 3 As shown in a and 3b, at a concentration of 2 μM, at 48 h, the migration distance of pamiparib was 237.34 μm, the migration distance of anlotinib was 120.03 μm, and the combined drug migration distance was only 66.93 μm. This shows that the combined use of pamiparib and anlotinib has a more significant inhibitory migration ability than single drug use, and the combination of the two drugs has a synergistic effect. Further reducing the drug concentration by 4 times, at 48 h, the combined drug group not only has a statistical difference with the solvent control group, but also has a significant statistical difference compared with the single drug group (such as Figure 3 c and 3d). In order to evaluate the effect of the combination of the two drugs on the longitudinal migration ability, a Transwell experiment was performed. The drug concentration of 0.5 μM was also selected. The results are shown in Figure 3 As shown in Figures e and 3f, the number of cells migrated by pamiparib (0.5 μM) was 261, the number of cells migrated by anlotinib (0.5 μM) was 177, and the number of cells migrated by pamiparib (0.5 μM) combined with anlotinib (0.5 μM) was only 15. This shows that the combined drug still has a significant inhibitory effect on the longitudinal migration of ovarian cancer A2780 cells compared with single drug use. Therefore, the combination of pamiparib and anlotinib has a more significant inhibitory effect on migration than single drug use.
[0063] At the same time, it was also demonstrated that when pamiparib (2 μM) and anlotinib (2 μM) were used in combination, the two drugs had a synergistic effect.
[0064] Example 4 Pamiparib combined with anlotinib inhibits ovarian cancer stem cells
[0065] Tumor stem cells are an important cause of tumor drug resistance and recurrence. The present invention uses tumor sphere formation experiment, limiting dilution experiment, real-time quantitative fluorescence PCR reaction experiment and protein blotting (Western Blot) to detect the inhibition of tumor stem cell activity. When tumor cells are placed in an environment where they cannot adhere to the wall and special culture medium, normal cancer cells will die due to lack of nutrition, while tumor stem cells will grow in suspension into a sphere. By observing the number and size of these spheres, the stemness of tumor cells can be reflected.
[0066] (1) Tumor spheroid formation experiment: Cells in the logarithmic growth phase were cultured at a rate of 1×10 5 10 μL of dimethyl sulfoxide was added to the solvent control group after the cells adhered to the wall, and the experimental group was added with an equal volume of 2 μM pamiparib and 2 μM anlotinib alone and 2 μM pamiparib and 2 μM anlotinib mixed solution, and the drugs were treated for 48 hours. The cells in the corresponding wells were digested with trypsin, and the digestion was terminated with cell culture medium, centrifuged, and PBS was centrifuged twice. The supernatant was discarded, and the cells of each group were resuspended in serum-free tumor sphere formation medium (DMEM: F12 was added with 20 ng / mL epidermal growth factor (EGF), 20 ng / mL basic fibroblast growth factor (bFGF), and 2% 50× serum-free additive (B27)). The cells of each group were counted and inoculated in a low-adhesion 24-well plate at a density of 1000 per well. Three replicates were set for each concentration gradient. The well plates were transferred to a cell culture incubator and cultured. After seven days, the cells were photographed and counted under a microscope.
[0067] like Figure 4 As shown in the tumor sphere photo in a, the combined drug group can significantly inhibit the size of stem cell spheres. Suspension spheres larger than 100 μm were counted as one stem cell clone sphere. By comparing the tumor sphere formation rate ( Figure 4 b) It can be seen that the formation rate of the combination of pamiparib and anlotinib was only 5, while that of the solvent control group was 20, that of the single drug pamiparib was 16, and that of anlotinib was 15, which has a more significant ability to inhibit tumor sphere formation. The combination of the two drugs has a synergistic effect.
[0068] (2) Limiting dilution experiment: Cells in the logarithmic growth phase were diluted to 1×10 5Each well was inoculated with 2 mL of 10 μL of DMSO and cultured in a 6-well plate at 37°C and 5% CO2 for 24 h. After the cells adhered to the wall, 10 μL of dimethyl sulfoxide was added to the solvent control group, and an equal volume of 2 μM pamiparib and 2 μM anlotinib alone and 2 μM pamiparib and 2 μM anlotinib mixed solution was added to the experimental group for 48 h. The cells in the corresponding wells were digested with trypsin, and the digestion was terminated with cell culture medium, centrifuged, and PBS was centrifuged twice. The supernatant was discarded, and the cells of each group were resuspended in serum-free tumor sphere formation medium (DMEM: F12 was added with 20 ng / mL epidermal growth factor (EGF), 20 ng / mL basic fibroblast growth factor (bFGF), and 2% 50× serum-free additive (B27)). The number of cells was calculated and inoculated in a 96-well plate. Each sample was divided into five groups according to the number of cells, namely 200, 100, 50, and 20 in a decreasing gradient, with 8 to 10 replicate wells set up in each group. The cells were counted after 7 to 10 days of culture in the incubator. Data processing was analyzed using the limit analysis online program.
[0069] like Figure 4 As shown in c, the blue solid line and the blue dotted line represent the solvent control group, the green solid line and the green dotted line represent 0.5 μM pamiparib, the black solid line and the black dotted line represent 0.5 μM anlotinib, and the red solid line and the red dotted line represent the combination of 0.5 μM pamiparib and 0.5 μM anlotinib. The slope represents the probability of sphering. The larger the slope, the lower the probability of sphering, and vice versa. Figure 4 As shown in Figure 2, the slope of pamiparib (0.5 μM) combined with anlotinib (0.5 μM) is larger than that of the solvent control group and the single drug group, which means that the probability of forming tumor clones is the lowest. In addition, as shown in Table 2, the probability of stem cells forming tumor clones in pamiparib combined with anlotinib is 1 / 186.7, which is significantly lower than that in the single drug group and the solvent control group. This shows that after the two drugs are combined, the inhibitory effect on the sphering ability of ovarian cancer stem cells is also very significant under the condition of extreme dilution, indicating that the activity of ovarian cancer stem cells can be effectively inhibited.
[0070] Table 2 The probability of pamiparib combined with anlotinib inhibiting the formation of tumor clones by ovarian cancer stem cells
[0071]
[0072] At the same time, it was also demonstrated that when pamiparib (2 μM) and anlotinib (2 μM) were used in combination, the two drugs had a synergistic effect.
[0073] Example 5 In vivo pharmacodynamics verification of pamiparib combined with anlotinib
[0074] (1) Establishment of BALB / C nude mouse ovarian cancer model
[0075] Four-week-old BALB / C female nude mice were selected and adapted for 1 week. The density of the injection was 5×10 7 100 μL of A2780 cell suspension per nude mouse. When the tumor volume grows to about 100 mm 3 After about 12 days, the model was successfully built.
[0076] (2) Grouping of tumor-bearing mice and administration method
[0077] The tumor volume of each mouse was measured with a vernier caliper, and the mice were divided into cages according to the principle that there was no significant difference in the average value of each drug-administered group. There were 4 mice in each group, and the grouping was as follows:
[0078] (a) Model group: The mice were given the same volume of 5% (w / v, mass concentration) sodium carboxymethylcellulose solution.
[0079] (b) Pamiparib group: 15 mg / kg, administered daily for 16 days.
[0080] (c) Anlotinib group: 1.5 mg / kg, administered daily, and stopped after 14 days.
[0081] (d) Pamiparib combined with anlotinib group: Pamiparib 10 mg / kg and anlotinib 1 mg / kg were administered simultaneously, where pamiparib was administered daily for 16 days, and anlotinib was administered daily and stopped after 14 days.
[0082] The administration method was oral gavage. Pamiparib and anlotinib were dissolved in 5% (w / v, mass concentration) sodium carboxymethylcellulose.
[0083] (3) Pharmacodynamic and biochemical index testing
[0084] (i) Changes in mouse tumor volume: After administration, the tumor volume of the mouse was measured with a vernier caliper every 2 days and recorded. A line graph of the changes in mouse tumor volume was drawn. The calculation formula for tumor volume is: V = 1 / 2 × a × b 2 V = mouse tumor volume; a = the long diameter of the mouse tumor; b = the short diameter of the mouse tumor.
[0085] (ii) Mouse body weight: After administration, the mouse body weight was weighed and recorded every 2 days. A line graph of the mouse body weight change was drawn.
[0086] (iii) Collection of serum and tissues: Mice were killed after 12 hours of fasting. Blood was collected from the femoral artery and placed in anticoagulant tubes containing sodium heparin. The blood was centrifuged and the supernatant was collected. The mice were dissected, and the tumor mass, heart, liver, spleen, lung, and kidney were weighed and recorded. They were then washed in physiological saline and photographed. All tissues were stored in a -80°C refrigerator for subsequent experiments.
[0087] (iv) Biochemical index detection: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are important indicators for evaluating liver disease function and were measured according to the instructions of Nanjing Jiancheng ALT and AST detection kits.
[0088] (4) In vivo pharmacodynamic results:
[0089] For single drug use, pamiparib 15 mg / kg and anlotinib 1.5 mg / kg were used. For combination therapy, the dosage was reduced by 2 / 3 times, i.e. pamiparib 10 mg / kg combined with anlotinib 1 mg / kg. After 13 days of tumor growth and 16 days of drug administration, Figure 5 As shown in (a), the tumor volume of the pamiparib combined with anlotinib group was inhibited to a certain extent compared with the model group. Only the combined drug group was different from the model group and had a strong statistical significance. Pamiparib was different from the model group, but there was no statistical significance. Anlotinib had a difference between the two groups, but it was only slightly statistically significant. At the same time, the combination of drugs was different from the two groups of single drugs, and it was also statistically significant. It shows that the combination of the two drugs can well control the growth of tumors in vivo.
[0090] After the mice were killed, the tumors were photographed and weighed. Figure 5 (b) and (c) are photos and masses of tumors treated with pamiparib combined with anlotinib. The results show that the tumor size of the combined drug group has visibly decreased. At the same time, the tumor mass of the combined drug group is significantly lower than that of the model group and the two single drug groups, indicating that the combination of the two drugs can inhibit tumor growth in mice in vivo. Body weight is an indicator for evaluating drug toxicity. Whether the body weight is normal or not is absolutely related to the degree of drug toxicity. Figure 6 a. Whether it is used alone or in combination, there is no difference in the weight of mice and no statistical significance. This shows that after the combination of drugs, there is no toxicity in the body. ALT and AST are important indicators for evaluating liver toxicity. We took blood from the brachial artery, extracted the serum of mice, and evaluated ALT and AST. We found that Figure 6 b. There is no significant difference between the combination of pamiparib and anlotinib on ALT and AST, indicating that the drug combination has almost no toxicity to the liver in vivo, which also provides a reasonable basis for clinical practice.
[0091] At the same time, it was also demonstrated that when pamiparib (2 μM) and anlotinib (2 μM) were used in combination, the two drugs had a synergistic effect.
[0092] Example 6 Verification of the mechanism of action of pamiparib combined with anlotinib
[0093] The immunoblotting method was used to further verify the mechanism of action of the combined use of the two drugs. The specific steps are as follows:
[0094] (1) Extraction of cell proteins
[0095] Cells in the logarithmic growth phase were taken at 3×10 5 The cells were inoculated at a density of 100 / mL in a 6-well plate and cultured in a cell culture incubator at 37°C and 5% for 24 hours. 10 μL of dimethyl sulfoxide was added to the solvent control group, and 10 μL of 2 μM pamiparib and 2 μM anlotinib alone and 2 μM pamiparib and 2 μM anlotinib mixed solution were added to each well of the experimental group, 10 μL per well, and the drug was continuously applied for 48 hours after addition. A mixed solution of high-efficiency RIPA (RadioImmunoprecipitationAssay) lysis buffer (purchased from Solebo) and protease inhibitors (purchased from MedChemExpress) was prepared in advance at a ratio of 100:1 (volume ratio). The culture medium was discarded, and the cells were washed twice with 1×PBS in an ice bath. On ice, 120-150 μL of a mixed solution of high-efficiency RIPA lysis buffer and protease inhibitors was added to each well. The solution was applied for 10 minutes. Centrifuged at 4°C and 13500 rpm for 30 minutes. The supernatant was taken after the centrifugation.
[0096] (2) Determination of protein concentration
[0097] According to the instructions of the BCA protein concentration detection kit (purchased from Solebol), the OD value was measured and the protein concentration was calculated based on the standard curve.
[0098] (3) SDS-PAGE electrophoresis
[0099] According to the volume of the protein sample, add 1 / 5 volume of 6×SB buffer and boil at 100℃ for 5 minutes to fully denature the protein, and put it in the refrigerator for use. Use a PAGE color rapid gel preparation kit with a mass concentration of 7.5% or 10%, prepare the gel according to the kit instructions, mix the sample and load it. Perform electrophoresis at 200V and 300mA. Note: 6×SB buffer preparation method: 7mL0.5 M Tris-HCl buffer (pH 6.8), 1g SDS, 3mL glycerol, 0.93g dithiothreitol, 1mg bromophenol blue, mix well.
[0100] (4) Transfer
[0101] After the protein is separated by SDS-PAGE gel electrophoresis, remove the gel, transfer it to Blotting buffer, soak it thoroughly, and then place it on a PVDF membrane. Voltage 15V, current 300mA, transfer membrane 1h 40min. Note: Blotting buffer preparation method: 32.28g Tris-HCl and 144.11g glycine are dissolved in 1L double distilled water, take 100mL of the above solution, add 200mL methanol and 700mL double distilled water, mix well and set aside.
[0102] (5) Closed
[0103] Place the PVDF membrane in 5% skim milk powder blocking solution. Block on a shaker at room temperature for 1 hour. After blocking, wash the PVDF membrane 3 times with PBST solution. Note: Blocking solution preparation method: 0.5g skim milk powder is added to 10mL PBST solution (1×PBS / Tween 20, 100:1, v / v, volume ratio) and mixed.
[0104] (6) Primary and secondary antibody reactions
[0105] Take out the primary antibody to be reacted, cut the PVDF membrane according to the molecular size of the primary antibody, and put it into the centrifuge bucket containing the primary antibody. Place the centrifuge bucket on the roller to allow the target primary antibody liquid to fully infiltrate the PVDF membrane. Incubate at 4℃ overnight and block.
[0106] Remove the primary antibody, put it in the incubation box, wash it 3 times with PBST at room temperature on a shaker, 10 minutes each time. Protect from light, immerse it in a centrifuge bucket containing the secondary antibody, soak it for 1 hour at room temperature, wash it again with PBST 3 times, 10 minutes each time, and finally use an infrared imaging membrane scanner to detect the results.
[0107] Mechanism of action Figure 7 As shown, pamiparib combined with anlotinib inhibits p-PI3K and then p-Akt, thereby inhibiting the expression of Bcl-2, a downstream apoptosis-related protein, and the increase in BAX expression. The expression of N-cadherin, a protein related to migration, is downregulated, and the expression of E-cadherin is increased. The stem cell-related proteins SOX2 and ALDH1A1 are downregulated. At the same time, HIF1-α is downstream of PI3K / Akt, and HIF1-α is inhibited, which means that DNA homologous recombination repair is inhibited and the sensitivity of PARP inhibitors is increased. Therefore, it is shown that the combination of the two drugs in vitro works through the PI3K / Akt signaling pathway and the stem cell signaling pathway. According to literature reports, the PI3K / Akt signaling pathway is closely related to the stem cell signaling pathway, and there is an upstream and downstream relationship, which affects the proliferation, metastasis, recurrence and drug resistance of tumor cells.
[0108] Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells are transformed into mesenchymal cells with migration and invasion capabilities under specific conditions. This process not only plays a key role in physiological processes such as embryonic development and tissue repair, but is also closely related to the occurrence and development of various diseases, including cancer. EMT gives cells the ability to metastasize and invade, including stem cell characteristics, reduced apoptosis, and promoted immunosuppression. The present invention also verifies the downregulation of EMT-related protein N-cadherin and the upregulation of E-cadherin, indicating the inhibition of cell migration ability after combined medication. In addition, the downregulation of SOX2 and ALDH1A1 proteins was further verified by immunoblotting, which all indicated the inhibition of ovarian cancer stem cell characteristics after combined medication, thereby reducing the drug resistance of cancer cells and enhancing the anti-tumor effect.
[0109] There is no clinical application of a combined drug strategy targeting tumor stem cells in the prior art. The present invention provides a synergistic composition for inhibiting ovarian cancer and its tumor stem cells, thereby achieving the purpose of treating the recurrence and drug resistance of ovarian cancer.
[0110] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions, changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.
Claims
1. A synergistic composition for inhibiting ovarian cancer and its tumor stem cells, Features: The composition consists of pamiparib and anlotinib in combination.
2. The composition according to claim 1, Features: The mass ratio of pamiparib and anlotinib when used in combination is 0.1-50:
1.
3. The composition according to claim 1 or 2, Features: When the composition is used, the administration method of the combination of pamiparib and anlotinib is simultaneous administration or sequential administration.
4. Use of the composition according to any one of claims 1 to 3 in the preparation of a drug for treating recurrence and / or drug resistance of ovarian cancer.
5. The use according to claim 4, Features: Pamiparib and anlotinib in the composition inhibit the characteristics of human ovarian cancer stem cells, thereby synergistically inhibiting the proliferation, cloning and migration of ovarian cancer, and achieving the treatment of recurrence and drug resistance of ovarian cancer by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
6. Use of the composition according to any one of claims 1 to 3 in the preparation of a drug for inhibiting the growth of ovarian cancer tumors in BALB / C nude mice in vivo.
7. The use according to claim 6, Features: Pamiparib and anlotinib in the composition inhibit the growth of ovarian cancer in nude mice by inhibiting the characteristics of ovarian cancer stem cells, and achieve the purpose of synergistically treating ovarian cancer by affecting the stem cell signaling pathway related to the PI3K / AKT signaling pathway.
8. Use of the composition according to any one of claims 1 to 3 in the preparation of a drug for inhibiting ovarian cancer tumor stem cells.
9. Use of the composition according to any one of claims 1 to 3 in the preparation of a drug for inhibiting the migration of ovarian cancer cells.
10. Use of the composition according to any one of claims 1 to 3 in the preparation of a drug for inhibiting ovarian cancer cell clone formation.
